909 related articles for article (PubMed ID: 17591566)
1. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
2. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
3. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
4. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
5. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
6. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
7. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET in children with lymphomas.
Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
12. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
13. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
15. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
Sioka C
Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
[TBL] [Abstract][Full Text] [Related]
16. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
17. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
19. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
Mikosch P
Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
[TBL] [Abstract][Full Text] [Related]
20. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
